IDEAYA Biosciences price to sales ratio IDYA
Market value divided by revenue over the last twelve months, since 2021.
- Today, Nov 2, 2026
- 13.0×
- 5-year median
- 22.2×
- Against its 5-year history
- 4th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 12.5× to 200×
- Peer median
- 2.7×
IDEAYA Biosciences' price to sales ratio is 13.0× as of Nov 2, 2026.
That is below its 5-year median of 22.2×, lower than on 96% of days in the last 5 years.
Over that time it ranged from 12.5× in Sep 2022 to 200× in Jul 2024.
The median for 10 large drugmakers of a similar size is 2.7×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 13.0× | 13.0× | 16.5× |
| 2025 | 184× | 184× | 184× |
| 2024 | 196× | 94.1× | 200× |
| 2023 | 97.7× | 13.0× | 97.7× |
| 2022 | 17.5× | 12.5× | 23.0× |
| 2021 | 25.6× | 23.2× | 29.0× |
Against its peers
Companies in Drug Manufacturers - General nearest IDEAYA Biosciences' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| IDYAIDEAYA Biosciences | 13.0× |
| NRIXNurix Therapeutics | 4.0× |
| OGNOrganon | 0.6× |
| LQDALiquidia | 8.3× |
| ARQTArcutis Biotherapeutics | 8.5× |
| PBHPrestige Consumer Healthcare | 2.1× |
| HRMYHarmony Biosciences | 2.3× |
| INDVIndivior Pharmaceuticals | 3.1× |
| ANIPANI Pharmaceuticals | 1.7× |
| PAHCPhibro Animal Health | 1.0× |
| LGNDLigand Pharmaceuticals | 21.1× |
| Peer median | 2.7× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on IDEAYA Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.